Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
MAP6 antisense RNA 1 (MAP6-AS1) is a long non-coding RNA gene transcribed from the opposite strand of the MAP6 locus. Antisense RNAs typically act to modulate the expression of their sense coding genes via epigenetic or post-transcriptional regulation, including mechanisms like chromatin remodeling, DNA methylation, transcriptional interference, and mRNA stabilization or degradation. MAP6-AS1 is part of a growing class of antisense lncRNAs, which can exert important regulatory effects in various tissues; however, its specific biological roles and disease associations have not yet been clarified[2][3]. There are no established drug interactions, clinical biomarkers, or safety concerns linked to this RNA at present. The nomenclature and molecular classification are correct according to current genomic sources[3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on MAP6 antisense RNA 1 (MAP6-AS1).